onr:"swepub:oai:DiVA.org:liu-112822"
Search: onr:"swepub:oai:DiVA.org:liu-112822" > A 2-year observatio...
- 1 of 1
- Previous record
- Next record
- To hitlist
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial
-
- Ziemssen, Tjalf (author)
- Klinikum Carl Gustav Carus, Germany
-
- Bajenaru, Ovidiu A. (author)
- Carol Davila University of Medical and Pharm, Romania
-
- Carra, Adriana (author)
- Hospital Britanico Buenos Aires, Argentina
- show more...
- Lander Delgado, Rafael H. (author)
- show less...
- (creator_code:org_t)
- 2014-08-14
- 2014
- English.
- In: Journal of Neurology. - : Springer Verlag (Germany). - 0340-5354 .- 1432-1459. ; 261:11, s. 2101-2111
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Studies suggest that patients with relapsing-remitting multiple sclerosis (RRMS) who do not benefit from other disease-modifying treatments (DMTs) may benefit from converting to glatiramer acetate (GA). COPTIMIZE was a 24-month observational study designed to assess the disease course of patients converting to GA 20 mg daily from another DMT. Eligible patients had converted to GA and had received prior DMT for 3-6 months, depending on the reasons for conversion. Patients were assessed at baseline and at 6, 12, 18, and 24 months. In total, 672 patients from 148 centers worldwide were included in the analysis. Change of therapy to GA was prompted primarily by lack of efficacy (53.6 %) or intolerable adverse events (AEs; 44.8 %). Over a 24-month period, 72.7 % of patients were relapse free. Mean annual relapse rate decreased from 0.86 [95 % confidence interval (CI) 0.81-0.91] before the change to 0.32 (95 % CI 0.26-0.40; p less than 0.0001) at last observation, while the progression of disability was halted, as the Kurtzke Expanded Disability Status Scale (EDSS) scores remained stable. Patients improved significantly (p less than 0.05) on measures of fatigue, quality of life, depression, and cognition; mobility scores remained stable. The results indicate that changing RRMS patients to GA is associated with positive treatment outcomes.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Keyword
- Disease-modifying therapy; Glatiramer acetate; Multiple sclerosis; RRMS
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Journal of Neurology (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Ziemssen, Tjalf
- Bajenaru, Ovidiu ...
- Carra, Adriana
- de Klippel, Nina
- de Sa, Joao C.
- Edland, Astrid
- show more...
- Frederiksen, Jet ...
- Heinzlef, Olivie ...
- Karageorgiou, Kl ...
- Lander Delgado, ...
- Landtblom, Anne- ...
- Macias Islas, Mi ...
- Tubridy, Niall
- Gilgun-Sherki, Y ...
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Neurology
- Articles in the publication
- Journal of Neuro ...
- By the university
- Linköping University
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
